Case reportParkinsonism–hyperpyrexia syndrome: The role of electroconvulsive therapy
Introduction
Neuroleptic malignant syndrome (NMS) is serious and potentially fatal complication of neuroleptic therapy. Neuroleptic malignant syndrome is characterized by extrapyramidal symptoms, altered consciousness, hyperthermia, autonomic dysfunction and an elevated creatine kinase (CK) level occurring in the context of a neuroleptic medication.1
Patients with clinically advanced Parkinson’s disease (PD) have been shown to be at high risk of NMS, especially after the withdrawal of anti-parkinsonian medication.2 A neuroleptic malignant-like syndrome (NMLS) has also been shown to occur in the absence of any change to the anti-parkinsonian medication regimen.3 The increased risk in parkinsonian disorders is likely to be secondary to central dopaminergic suppression.4 In recognition of the fact that NMS can be triggered by factors other than exposure to neuroleptic medication, there has been a nosological shift in the research literature towards the term parkinsonism–hyperpyrexia syndrome (PHS);[5], [6] however, it has also been referred to as NMLS or malignant syndrome (MS) in PD.7
Electroconvulsive therapy (ECT) is recognised to be a safe and effective treatment for a range of affective and catatonic disorders in patients with neurological disorders.8 Case reports have also indicated that ECT has therapeutic effects in patients with severe PD but without affective or psychotic disorders.9 Multiple case reports have demonstrated the effectiveness of ECT in the treatment of NMS.10 However, an extensive search of Medline, EMBASE, PubMed and CINAHL databases showed no case reports of ECT in the treatment of patients with PHS.
Section snippets
Case report
A 58-year-old man presented with a 2-week history of increasing rigidity and agitation, associated with a confusional state with psychotic features. He developed persecutory and nihilistic delusions during this 2-week period and was noted by his family to be responding to visual hallucinations.
There was a 10-year history of PD, which had been stable over the past 4 years with no recent medication adjustments. The patient also had a background history of mixed anxiety and depression that had
Discussion
This is the first published case report highlighting the effectiveness of ECT in the treatment of PHS. Thus far, the literature has focused on medical therapy for this potentially fatal condition, although the effectiveness of ECT in the treatment of NMS in patients without PD has been acknowledged in numerous case reports.10
The nosology surrounding the condition of PHS is confusing. The term ‘PHS’ has been used in the literature to refer to a clinical syndrome that is essentially identical to
References (20)
- et al.
Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group
Parkinsonism Relat Disord
(2003) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Br J Anaesth
(2005)- et al.
Symptoms of neuroleptic malignant syndrome in 82 consecutive patients
Am J Psychiatry
(1986) - et al.
Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease
Neurology
(1999) - et al.
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease
Int Med
(1992) - et al.
Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome
Neurol Neurosurg Psychiatry
(2001) - et al.
Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome
Semin Neurol
(1991) - et al.
Reply: Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal
Mov Disord
(2005) - et al.
ECT in the treatment of patients with neurological and somatic disease
Int J Psychiatry Med
(1994) - et al.
Maintenance electroconvulsive therapy for Parkinson’s disease
Convuls Ther
(1997)
Cited by (24)
Life-threatening parkinsonism-hyperpyrexia syndrome following bilateral deep brain stimulation of the subthalamic nucleus
2018, Neurologia i Neurochirurgia PolskaParkinsonism hyperpyrexia syndrome
2018, NeurologiaThermoregulation and age
2018, Handbook of Clinical NeurologyCitation Excerpt :The mechanism is probably similar in end-of-life hyperthermia of carcinomatous patients with brain metastases. Parkinson disease in its subacute motor deterioration is often accompanied by high Tc (parkinsonism-hyperpyrexia syndrome) (Meagher et al., 2006; Umemura et al., 2014). Artificial hyperthermia (Cremer and Kalkman, 2007) is also used in therapy (e.g., for neoplastic diseases); the cerebral consequences are similar to those in previous cases: brain edema, intracranial hypertension, cerebral hemorrhage.
Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy
2011, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Ozer et al. (2005) reported about a patient with PD, in which ECT was effective against neuroleptic malignant syndrome as the result of the sudden termination of high-dose levodopa treatment, and depressive and psychotic symptoms. Meagher et al. (2006) reported about a patient with PD, in which a good response to eight ECT treatments was achieved, with resolution of his confusional state and associated psychotic phenomena. Kamigaichi et al. (2009) reported about a patient with PD, in which ECT was effective against catatonic and psychotic symptoms.
Pharmacologically-induced neurocatastrophes
2010, NeurologiaNeuroleptic malignant syndrome: Further lessons from a case report
2010, Psychosomatics